Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease
Open Access
- 22 July 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (11) , 1499-1512
Abstract
Glomerular disease is a leading cause of CKD and ESKD. Although diabetic kidney disease is the most common cause of glomerular disease, nondiabetic causes include malignancy, systemic autoimmune conditions, drug effects, or genetic conditions. Nondiabetic glomerular diseases are rare diseases, with a paucity of high-quality clinical trials in this area. Furthermore, late referral can result in poor patient outcomes. This article reviews the current management of nondiabetic glomerular disease and explores the latest developments in drug treatment in this area. Current treatment of nondiabetic glomerular disease aims to manage complications (edema, hypertension, proteinuria, hyperlipidemia, hypercoagulability, and thrombosis) as well as target the underlying cause of glomerular disease. Treatment options include renin-angiotensin-aldosterone system inhibitors, statins/nonstatin alternatives, loop diuretics, anticoagulation agents, immunosuppressives, and lifestyle and dietary modifications. Effective treatment of nondiabetic glomerular disease is limited by heterogeneity and a lack of understanding of the disease pathogenesis. Sodium-glucose cotransporter-2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs, such as finerenone), with their broad anti-inflammatory and antifibrotic effects, have emerged as valuable therapeutic options for a range of cardiorenal conditions, including CKD. ns-MRAs are an evolving drug class of particular interest for the future treatment of nondiabetic glomerular disease, and there is evidence that these agents may improve kidney prognosis in various subgroups of patients with CKD. The benefits offered by ns-MRAs may present an opportunity to reduce the progression of CKD from a spectrum of glomerular disease. Several novel ns-MRA are in clinical development for both diabetic and nondiabetic CKD.Keywords
This publication has 88 references indexed in Scilit:
- The Uncertainty Puzzle of Monoclonal Gammopathy of Renal Significance Without Detectable ClonesKidney International Reports, 2023
- Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney diseaseEuropean Journal of Internal Medicine, 2023
- Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: A systematic review and meta-analysisDiabetes Research and Clinical Practice, 2022
- Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trialClinical Research in Cardiology, 2022
- Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trialDiabetes & Metabolism, 2021
- Mineralocorticoid Receptor Antagonists: a Comprehensive Review of FinerenoneCurrent Cardiology Reports, 2020
- Evaluation of an Individualized Dose Titration Regimen of Patiromer to Prevent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney DiseaseESC Heart Failure, 2018
- Effect of Finerenone on Albuminuria in Patients With Diabetic NephropathyJAMA, 2015
- Discovery of BAY 94‐8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal DiseasesChemMedChem, 2012
- Effect of Spironolactone on Left Ventricular Systolic and Diastolic Function in Patients With Early Stage Chronic Kidney DiseaseThe American Journal of Cardiology, 2010